DAFNA Capital Management LLC
Nathan Fischel Los Angeles, CA 19 13Fs · since 2021 Q3
- AUM $440M
- positions 82
- period 2026 Q1
- QoQ +2.1%
- top 5 36.5%
- qoq N 10 E 4 A 17 R 27
- REVOLUTION MEDICINES INC - RVMD 12.8%
- SPDR S&P BIOTECH ETF 9.3%
- STEREOTAXIS INC 5.7%
- DAY ONE BIOPHARMACEUTICALS I - DAWNGBX 4.8%
- ATRICURE INC - ATRC 3.9%
- IDEAYA BIOSCIENCES INC 3.6%
- XENON PHARMACEUTICALS INC 3.3%
- CYTOKINETICS INC - CYTK 3.3%
- COMPASS PATHWAYS PLC - CMPS 3.0%
- NEKTAR THERAPEUTICS 2.7%
- ISHARES NASDAQ BIOTECH INDX - NDAQ 2.4%
- ARCUS BIOSCIENCES INC - RCUS 2.2%
- Other 43.0%
AUM over time
Holdings value
2026 Q1
$440M
+2.1% QoQ
Latest book
| REVOLUTION MEDICINES INC - RVMD | 12.85% | Reduce −3.9% | 580,678 | $97.25 | $56M | −23,836 | +$8M |
| SPDR S&P BIOTECH ETF | 9.25% | Reduce −5.3% | 318,505 | $127.73 | $41M | −18,000 | −$347 |
| STEREOTAXIS INC | 5.73% | 13,680,554 | $1.84 | $25M | — | — | |
| DAY ONE BIOPHARMACEUTICALS I - DAWNGBX | 4.77% | Reduce −2.1% | 978,463 | $21.44 | $21M | −20,700 | +$12M |
| ATRICURE INC - ATRC | 3.88% | 597,431 | $28.53 | $17M | — | — | |
| IDEAYA BIOSCIENCES INC | 3.61% | Reduce −5.9% | 476,740 | $33.32 | $16M | −30,000 | −$2M |
| XENON PHARMACEUTICALS INC | 3.32% | Reduce −12.9% | 250,772 | $58.15 | $15M | −37,167 | +$2M |
| CYTOKINETICS INC - CYTK | 3.26% | Reduce −41.4% | 217,497 | $65.91 | $14M | −153,500 | −$9M |
| COMPASS PATHWAYS PLC - CMPS | 3.04% | Add +198.2% | 2,418,882 | $5.53 | $13M | +1,607,836 | +$8M |
| NEKTAR THERAPEUTICS | 2.70% | Add +120.2% | 165,178 | $71.95 | $12M | +90,180 | +$9M |
| ISHARES NASDAQ BIOTECH INDX - NDAQ | 2.39% | Reduce −8.8% | 62,095 | $168.85 | $10M | −6,000 | −$1M |
| ARCUS BIOSCIENCES INC - RCUS | 2.18% | Add +2.9% | 443,829 | $21.60 | $10M | +12,500 | −$692 |
| NEUROCRINE BIOSCIENCES INC - NBIX | 2.12% | 70,615 | $131.74 | $9M | — | — | |
| LARIMAR THERAPEUTICS INC | 2.08% | Add +116.1% | 2,029,164 | $4.50 | $9M | +1,090,000 | +$6M |
| BICARA THERAPEUTICS INC - BCAX | 1.91% | Add +61.2% | 421,733 | $19.89 | $8M | +160,150 | +$4M |
| AXOGEN INC - AXGN | 1.88% | Reduce −47.6% | 249,960 | $33.13 | $8M | −226,866 | −$7M |
| BIOHAVEN LTD | 1.63% | Reduce −11.5% | 845,735 | $8.46 | $7M | −109,500 | −$4M |
| TANDEM DIABETES CARE INC | 1.55% | 355,208 | $19.17 | $7M | — | — | |
| DENALI THERAPEUTICS INC - DNLI | 1.39% | 318,500 | $19.20 | $6M | — | — | |
| CENTURY THERAPEUTICS INC - IPSC | 1.25% | Reduce −12.9% | 2,434,353 | $2.26 | $6M | −359,233 | +$3M |
| DEXCOM INC - DXCM | 1.23% | Reduce −2.3% | 86,279 | $62.80 | $5M | −2,000 | −$441 |
| KALVISTA PHARMACEUTICALS INC | 1.22% | Reduce −25.1% | 267,402 | $20.13 | $5M | −89,400 | −$380 |
| ASCENDIS PHARMA A/S | 1.21% | Reduce −17.7% | 23,177 | $228.73 | $5M | −5,000 | −$707 |
| MBX BIOSCIENCES INC | 1.19% | Add +6.2% | 175,465 | $29.85 | $5M | +10,200 | +$25 |
| INOGEN INC | 1.19% | Add +2.2% | 845,179 | $6.18 | $5M | +18,108 | −$335 |
| SYNDAX PHARMACEUTICALS INC | 1.16% | Reduce −21.8% | 217,355 | $23.36 | $5M | −60,500 | −$760 |
| ALKERMES PLC | 1.12% | Add +7.1% | 139,482 | $35.36 | $5M | +9,234 | +$1M |
| STOKE THERAPEUTICS INC | 0.97% | Add +20.2% | 130,875 | $32.56 | $4M | +22,000 | +$806 |
| BIOCRYST PHARMACEUTICALS INC - BCRX | 0.93% | Add +2.9% | 430,248 | $9.52 | $4M | +11,993 | +$834 |
| GALAPAGOS NV | 0.89% | 130,175 | $30.00 | $4M | — | — | |
| IMMUNOVANT INC | 0.85% | 150,524 | $24.84 | $4M | — | — | |
| EDGEWISE THERAPEUTICS INC | 0.80% | Reduce −29.7% | 112,236 | $31.50 | $4M | −47,500 | −$428 |
| MAPLIGHT THERAPEUTICS INC | 0.79% | Add +18.9% | 171,006 | $20.33 | $3M | +27,242 | +$951 |
| ALLOGENE THERAPEUTICS INC - ALLO | 0.76% | Reduce −0.7% | 1,370,118 | $2.44 | $3M | −10,000 | +$1M |
| PROCEPT BIOROBOTICS CORP | 0.68% | 120,000 | $25.01 | $3M | — | — | |
| ALIGN TECHNOLOGY INC - ALGN | 0.58% | Reduce −6.3% | 15,000 | $171.43 | $3M | −1,000 | +$73 |
| PROQR THERAPEUTICS N V | 0.58% | 1,567,561 | $1.62 | $3M | — | — | |
| CYBIN INC - CYBN | 0.54% | Add +9.5% | 498,361 | $4.80 | $2M | +43,343 | −$1M |
| RAPPORT THERAPEUTICS INC | 0.53% | 75,000 | $31.29 | $2M | — | — | |
| INSULET CORP - PODD | 0.52% | Add +58.2% | 10,870 | $209.84 | $2M | +4,000 | +$328 |
| STRUCTURE THERAPEUTICS INC | 0.51% | Add +25.7% | 46,500 | $48.20 | $2M | +9,500 | −$332 |
| IMMATICS NV | 0.51% | Reduce −13.5% | 225,860 | $9.84 | $2M | −35,278 | −$519 |
| CELLDEX THERAPEUTICS INC - CLDX | 0.49% | 68,518 | $31.72 | $2M | — | — | |
| LEXEO THERAPEUTICS INC | 0.49% | Add +10.6% | 377,059 | $5.74 | $2M | +36,200 | −$1M |
| ALECTOR INC - ALEC | 0.44% | 908,351 | $2.15 | $2M | — | — | |
| VIKING THERAPEUTICS INC | 0.44% | 59,516 | $32.54 | $2M | — | — | |
| KURA ONCOLOGY INC | 0.44% | 235,868 | $8.13 | $2M | — | — | |
| PROFOUND MEDICAL CORP | 0.39% | Reduce −7.9% | 263,005 | $6.48 | $2M | −22,705 | −$544 |
| FULCRUM THERAPEUTICS INC | 0.36% | New | 205,000 | $7.67 | $2M | +205,000 | +$2M |
| AQUESTIVE THERAPEUTICS INC - AQST | 0.35% | Reduce −2.0% | 368,415 | $4.15 | $2M | −7,500 | −$899 |
| ASTRIA THERAPEUTICS INC - CATBUSD | — | Exit | 0 | $13.09 | — | −304,775 | −$4M |
| ERASCA INC | — | Exit | 0 | $3.72 | — | −254,436 | −$947 |
| BRAINSWAY LTD - BWAY | — | Exit | 0 | $19.05 | — | −12,965 | −$247 |
| PERSPECTIVE THERAPEUTICS INC | — | Exit | 0 | $2.76 | — | −50,000 | −$138 |
Showing top 50 of 82 by value · full holdings → · all activity →
* Reported price is value ÷ shares from the 13F as of period end — not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2025 Q4. Click column headers to sort · click New / Exit / Add / Reduce to promote that move type to the top. Among managers we track.
filings history
19 periods · normalized AUM · click period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
19 processed 13Fs · since 2021 Q3